Affiliation:
1. Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 1W-3750, 9000 Rockville Pike, Bethesda, MD 20892-1104, 301-496-4256 Facsimile 301-451-7010,, United States
Abstract
Despite great progress in the curative treatment of acute leukemia, outcomes for those with
relapsed and/or chemotherapy-refractory disease remain poor. Current intensive cytotoxic therapies can
be associated with significant morbidity and novel therapies are needed to improve outcomes. Immunotherapy
based approaches provide an alternative mechanism of action in the treatment of acute leukemia.
Due to cell surface antigen expression, leukemia in particular is amenable to targeted therapies,
such as antibody-based therapy. Based on the potential for non-overlapping toxicity, the possibility of
synergistic action with standard chemotherapy, and by providing a novel method to overcome chemotherapy
resistance, antibody-based therapies have shown potential for benefit. Modifications to standard
monoclonal antibodies, including drug conjugation and linkage to T-cells, may further enhance efficacy
of antibody-based therapies. Identifying the ideal timing for incorporation of antibody-based therapies,
within standard regimens, may lead to improvement in overall outcomes. This article will provide an
overview of antibody-based therapies in clinical development for the treatment of acute leukemia in
children and adults, with a particular focus on the current strategies and future developments.
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献